PomegraModerna Stock Jumps 9% as mRNA Cancer Vaccine Clears Phase 3
Why is Moderna stock up today?
Moderna (MRNA) stock rose 9% to about $172 on Friday as Phase 3 data at ESMO 2026 confirmed intismeran cuts melanoma recurrence or death 49% versus Keytruda alone.
Key numbers
| Phase 2b risk reduction in recurrence or death | 49%vs Keytruda alone; HR 0.51 (95% CI 0.294–0.887) at 5-year follow-up |
|---|---|
| Phase 3 INTerpath-001 enrollment | 1,137 patientscompletely resected stage IIB–IV melanoma; 2:1 randomisation |
| MRNA gain on Phase 3 announcement day | +177%Aug 19, 2026 close $174.38 — largest single-day gain in company history (per [4]) |
| MRNA 1-month gain | +143%from pre-announcement close (~$63) to today (~$172) |
| Moderna cash and investments end Q2 2026 | $6.9Bprojected $4.7–5.2B year-end after $950M litigation settlement paid July |
| Moderna 2026 revenue guidance | Up to +10% YoYfrom 2025 base; ~$3.5B implied full-year |
What happened
Moderna (MRNA) stock rose 9% to about $172 on Friday as Phase 3 data at ESMO 2026 confirmed intismeran cuts melanoma recurrence or death 49% versus Keytruda alone. The Phase 3 INTerpath-001 trial tested 1,137 post-surgery melanoma patients and showed the personalized vaccine plus Merck's Keytruda beat Keytruda on its own on the primary recurrence-free survival endpoint and a key distant-metastasis survival goal. Intismeran is made-to-order for each patient, using mRNA to train the immune system against up to 34 tumor-specific mutation targets unique to that person's cancer. It is the first-ever personalized mRNA cancer therapy to clear a Phase 3 trial, validating five-year Phase 2b data showing a 49% reduction in recurrence or death, hazard ratio 0.51.
Why it matters
Intismeran is proof that mRNA technology — the same platform behind COVID vaccines — can fight cancer at a personalized, tumor-by-tumor level, a goal researchers have pursued for decades. For patients with high-risk melanoma after surgery, combining this vaccine with immunotherapy significantly reduces the chance the cancer comes back. The Phase 3 win opens the door to a regulatory filing that could produce the first approved personalized cancer vaccine in history.
Who this affects
- MarketbullishMedium impact
- Moderna hits multi-week high; biotech sector broadly lifts.
- CompanybullishHigh impact
- Moderna validates first oncology asset, reducing COVID revenue reliance.
- CompetitorsmixedLow impact
- BioNTech edges up on mRNA halo; Merck's Keytruda franchise expands.
- IndustrybullishHigh impact
- Personalized mRNA cancer vaccines become a proven treatment category.
Moderna vs Merck, BioNTech, Bristol-Myers Squibb
| ModernaMRNA:NASDAQ | ~$69B | +9% | +350% | N/A |
|---|---|---|---|---|
| MerckMRK:NYSE | $371B | — | +36% | ~16x |
| BioNTechBNTX:NASDAQ | $26B | — | — | — |
| Bristol-Myers SquibbBMY:NYSE | $136B | — | — | ~10x |
As of 2026-09-18
How we got here
ASCO 2026: 5-year Phase 2b data shows 49% recurrence cut (HR 0.51) vs Keytruda.
Phase 3 INTerpath-001 meets RFS and DMFS endpoints; MRNA surges 177%.
Moderna presents intismeran pipeline progress at Morgan Stanley Healthcare Conference.
Full Phase 3 data presented at ESMO 2026; MRNA gains another 9%.
What to watch
- BLA regulatory submission for intismeran in adjuvant melanoma.Q4 2026
- Full Phase 3 hazard ratios published in peer-reviewed journal.Q4 2026
- INTerpath-002 and -003 readouts in NSCLC and bladder cancer.2027
Educational content only. Not investment advice.
More briefsAll briefs →
Goldman Sachs Stock Falls 4% After CEO Flags Softer FICC, Higher Costs
Goldman Sachs (GS) fell 4% Wednesday as Solomon flagged softer Q3 bond trading and $500M in extra costs.
Gold Stalls at $4,307 as Post-Fed Dollar Surge Pins Bullion
Gold (XAU/USD) hit $4,235 six-week low after the Fed's first hike since 2023 lifted the dollar above 100.
Fluence Energy Stock Sinks 22% on Second Guidance Cut
Fluence (FLNC) slashes FY revenue to $2.4B on Houston delays; Barclays, Mizuho, Piper Sandler add Underweight.